Abstract
ABSTRACT The purpose of this article is to better understand the challenges of avoiding the dark side of technological innovation. Specifically, we analyse 10 public investigations started as a reaction to a major crisis in regenerative medicine at the Karolinska Institute, Sweden, associated with the clinician-scientist Paolo Macchiarini. We interpret the reaction as an attempt to restore the balance between the stimulation and regulation of technological innovation processes by clarifying ambiguities in the regulation at the interface between research and practice. We conceptualise these ambiguities as grey zones – situations when it is unclear if the benefits of experimentation outweigh its risks – and propose that grey zones are continually created and resolved as actors in innovation governance systems counterbalance the generation of novelty and the risk of negative unintended consequences.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
